MarketCap
Facebook
X
Telegram
Longeveron Market Cap | LGVN
As of August 31, 2026 Longeveron has a market cap of $ 118 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Longeveron
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.9 B | 14.4 B | 1.26 B | 61.2 M | 141 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.9 B | 61.2 M | 6.55 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
2.01 M | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
50.7 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Synthetic Biologics
SYN
|
1.29 M | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
1.73 B | - | - | $ 2.02 B | USA |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
BioLineRx Ltd.
BLRX
|
5.65 B | $ 2.6 | 5.56 % | $ 6.41 B |  Israel |
 |
Corner Growth Acquisition Corp.
COOL
|
109 M | - | -0.89 % | $ 114 M | USA |
 |
AgeX Therapeutics
AGE
|
29.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
BioMarin Pharmaceutical
BMRN
|
11.7 B | $ 64.67 | 0.11 % | $ 12.4 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Qilian International Holding Group Limited
QLI
|
68.2 M | - | -6.08 % | $ 184 M | China |
 |
Happiness Biotech Group Limited
HAPP
|
8.91 M | - | 1.35 % | $ 17.8 M | China |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
179 M | - | -13.47 % | $ 169 M | France |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
1.62 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
740 M | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
4.94 B | - | - | $ 4.9 B |  Britain |
 |
Завод ДИОД
DIOD
|
661 M | - | - | - |  Russia |
|
Galera Therapeutics
GRTX
|
7.65 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
1.44 B | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
376 K | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
624 M | - | 2.43 % | $ 254 M | Germany |
 |
Affimed N.V.
AFMD
|
527 M | - | -34.95 % | $ 21.5 M | Germany |
 |
C4 Therapeutics
CCCC
|
234 M | $ 3.85 | 0.12 % | $ 319 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
3.44 B | $ 23.78 | 1.13 % | $ 3.03 B | USA |
 |
Assembly Biosciences
ASMB
|
308 M | $ 34.07 | 0.17 % | $ 382 M | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
167 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
10.6 M | - | - | $ 12.5 M |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
1.31 M | $ 5.6 | 2.06 % | $ 3.74 M | USA |
 |
Codexis
CDXS
|
111 M | $ 1.59 | 0.3 % | $ 139 M | USA |
 |
Generation Bio Co.
GBIO
|
179 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Anika Therapeutics
ANIK
|
214 M | $ 21.1 | 1.25 % | $ 303 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
109 K | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
1.99 B | - | - | $ 3.37 B | China |
 |
Axsome Therapeutics
AXSM
|
8.67 B | $ 199.02 | 0.31 % | $ 9.9 B | USA |
 |
GlycoMimetics
GLYC
|
18.1 M | - | 9357.83 % | $ 1.01 B | USA |
 |
AnaptysBio
ANAB
|
1.52 B | $ 56.28 | 0.1 % | $ 1.62 B | USA |
 |
Aeterna Zentaris
AEZS
|
14.8 M | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
1.61 M | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.25 | 0.45 % | $ 14.1 M | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |